Article Text

other Versions

PDF
Burden of Illness, Visual Impairment, and Health Resource Utilisation of Patients with Neovascular Age-Related Macular Degeneration: Results from the United Kingdom Cohort of a Five-Country Cross-Sectional Study
  1. Andrew J Lotery (a.j.lotery{at}soton.ac.uk),
  2. Xiao Xu,
  3. Gergana Zlatava,
  4. Jane Loftus
  1. University of Southampton, United Kingdom
  2. Covance Market Access Services, United States
  3. Pfizer Inc, United States
  4. Pfizer Ltd, United Kingdom

    Abstract

    Background/aims: Quantitative data regarding the impact of neovascular age-related macular degeneration (NV-AMD) on individuals and society is a prerequisite for rational decision-making processes when evaluating alternative treatments for the disease.

    Methods: Seventy-five bilateral NV-AMD (patients) and 91 elderly non-AMD (controls) subjects forming the United Kingdom cohort of an international cross-sectional, observational study were independently analysed. Subjects completed a telephone survey including the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), the EuroQol (EQ-5D), the Hospital Anxiety and Depression Scale (HADS), history of falls, and health resource utilisation.

    Results: Patients with NV-AMD reported substantially worse vision-related functioning and overall well-being, including higher depression scores, than controls after adjusting for age, gender, and co-morbidities (adjusted mean scores: NEI-VFQ-25 overall 52.7 vs. 90.7, P<0.0001; EQ-5D 0.67 vs. 0.77, P=0.0273; HADS depression 6.8 vs. 4.0, P=0.0026). Significantly more patients reported a need for assistance with daily activities compared to controls (25.3% vs. 6.6%, P=0.003). Total annual healthcare utilisation costs were more than seven-fold higher for patients with AMD compared with controls (£3,823.89 vs. £517.05, respectively; P<0.0001)

    Conclusions: NV-AMD patients show a significant decline in quality of life and increased need for daily living assistance compared to a control population without AMD. With the availability of effective new therapies there is a need for improved early access to treatment.

    • burden of illness
    • health resource utilisation
    • neovascular age-related macular degeneration
    • quality of life

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.